Dopavision
Gabriela Burian has extensive experience in the medical field, beginning with a role as a Physician, General & Family Practice, Epidemiology at Municipal Hospital Orsova in 1990. Gabriela then worked as an Ophthalmic Medical Technician at Georgia Retina, PC in 1996, and as a Clinical Research Manager and Faculty Ophthalmology Masters at Emory University in 2000. In 2005, they joined Novartis Pharma AG as a Therapeutic Area Head Ophthalmology/ Global Program Medical Director, Global Program Medical Director/ Ophthalmology/ Lucentis, Medical Scientific Expert, and Sr. Clinical Research Scientist/ Clinical Communications Leader. In 2013, they moved to Roche as an Early Development Program Leader Ophthalmology. In 2014, they became Chief Medical Officer at Iconic Therapeutics and Executive Advisor at GBBiomed Advisors GmbH. In 2017, they took on the role of Consulting Chief Medical Officer at Novaliq GmbH, and in 2021 they became Consulting Chief Medical Officer at Dopavision.
Gabriela Burian received their MD from Victor Babeş University of Medicine and Pharmacy, Timişoara between 1984 and 1990, majoring in General Medicine. Gabriela then went on to pursue an MPH in Epidemiology at Emory University from 2000 to 2003.
This person is not in any offices
Dopavision
1 followers
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.